Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Treprostinil Palmitil Inhalation Powder in Hepatic Impairment
NCT07643155Phase 1Recruiting
- Sponsor
- Insmed Incorporated
- Start
- Jul 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of treprostinil palmitil in pulmonary arterial hypertension (PAH) (4 arms), sponsored by Insmed Incorporated. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Infinity, Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration and 5 more. Started Jul 2026; status: recruiting.
02
Drugs
treprostinil palmitil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT07643155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07643155.